Department of Anesthesiology, Albany Medical College, Albany, New York, USA.
Drugs Aging. 2010 May;27(5):417-33. doi: 10.2165/11536540-000000000-00000.
Opioid analgesics have an established role in the management of postoperative pain and cancer pain, and are gaining acceptance for the management of moderate to severe chronic noncancer pain, most notably chronic low back pain and osteoarthritis, that does not respond to other interventions. Many patients with chronic pain have co-morbid medical conditions that may complicate opioid therapy. Selecting the appropriate opioid requires knowledge of how individual opioids differ with respect to metabolism and interaction with concurrent medications, as well as the reasons why specific medical conditions may influence their efficacy and tolerability. Polypharmacy is a common complicating condition in the elderly and in patients with psychiatric illness, cancer, cardiovascular disease, diabetes mellitus or other chronic illnesses. Polypharmacy, though often necessary for patients with multiple medical conditions, also multiplies the risk of drug interactions. Pharmacokinetic drug interactions can increase or reduce exposure to the opioid or concurrent medications, reducing efficacy and/or tolerability and increasing toxicity. Pharmacodynamic interactions can enhance the depressive effects of opioids, compromising safety. Patients with impaired renal or hepatic function may have difficulty clearing or metabolizing opioids and concurrent medications, leading to increased risk of adverse events. Patients with cardiovascular, cerebrovascular or respiratory disease (including smokers of >/=2 packs/day with no other diagnosis) may be more susceptible to respiratory depression, bradycardia and hypotension with any opioid, and a few specific opioids pose additional risks. Patients with cerebrovascular disease, dementia, brain injury or psychiatric illness are more susceptible to opioid effects on the CNS, which can include euphoria, cognitive impairment and sedation. Appropriate opioid selection may mitigate these effects. Even in older patients, addiction, abuse and misdirection of prescribed opioids are of concern. Higher risk exists for patients with psychiatric illness, history of substance abuse, and identifiable substance abuse risk factors. Screening for abuse potential and vigilant patient monitoring should be routine. Opioids differ in their ability to produce euphoria, based on opioid receptor agonism, but substance abusers may be more influenced by availability, familiarity and cost factors. Consequently, opioid selection has limited influence on abuse potential but can facilitate ease of monitoring. This review provides an overview of opioid use in medically complicated patients and recommendations on how to optimize analgesia while avoiding adverse events and drug interactions in the clinical setting. Articles cited in this review were identified via a search of EMBASE and PubMed. Articles selected for inclusion discussed characteristics of specific opioids and general physiological aspects of opioid therapy in important patient populations.
阿片类镇痛药在术后疼痛和癌症疼痛的管理中具有既定的作用,并且越来越被接受用于治疗中度至重度慢性非癌性疼痛,尤其是慢性下背痛和骨关节炎,这些疼痛对其他干预措施没有反应。许多慢性疼痛患者伴有合并症,这可能会使阿片类药物治疗复杂化。选择合适的阿片类药物需要了解个体阿片类药物在代谢和与同时使用的药物相互作用方面的差异,以及特定医疗状况可能影响其疗效和耐受性的原因。同时使用多种药物是老年人和精神病、癌症、心血管疾病、糖尿病或其他慢性疾病患者的常见并发症。同时使用多种药物虽然对患有多种疾病的患者通常是必要的,但也会增加药物相互作用的风险。药代动力学药物相互作用会增加或减少阿片类药物或同时使用的药物的暴露量,从而降低疗效和/或耐受性并增加毒性。药效学相互作用会增强阿片类药物的抑制作用,从而危及安全性。肾功能或肝功能受损的患者可能难以清除或代谢阿片类药物和同时使用的药物,从而增加不良事件的风险。患有心血管、脑血管或呼吸系统疾病(包括无其他诊断但每天吸烟≥2 包的患者)的患者可能更容易出现任何阿片类药物引起的呼吸抑制、心动过缓和低血压,而少数特定阿片类药物则会带来额外的风险。患有脑血管疾病、痴呆、脑损伤或精神病的患者更容易受到阿片类药物对中枢神经系统的影响,包括欣快、认知障碍和镇静。适当的阿片类药物选择可能会减轻这些影响。即使在老年患者中,对处方阿片类药物的成瘾、滥用和误用也令人担忧。有精神病史、物质滥用史和可识别的物质滥用风险因素的患者风险更高。滥用潜力的筛查和对患者的严密监测应成为常规。阿片类药物根据阿片受体激动剂的不同而产生欣快感的能力不同,但物质滥用者可能更容易受到可用性、熟悉度和成本因素的影响。因此,阿片类药物的选择对滥用潜力的影响有限,但可以方便监测。本综述提供了在患有合并症的患者中使用阿片类药物的概述,并就如何在临床环境中优化镇痛效果同时避免不良事件和药物相互作用提出了建议。本文综述中引用的文章是通过对 EMBASE 和 PubMed 的搜索确定的。入选的文章讨论了特定阿片类药物的特征以及在重要患者人群中阿片类药物治疗的一般生理方面。